Re: randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.
暂无分享,去创建一个
[1] R. Theriault,et al. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study , 2000, The Lancet.
[2] Terry L. Smith,et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. , 2000, Journal of the National Cancer Institute.
[3] G. Hortobagyi,et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. , 1999, Annals of surgery.
[4] P. Pedrazzoli,et al. Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment. , 1999, Anticancer Research.
[5] Terry L. Smith,et al. Results and long term follow‐up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin‐containing chemotherapy , 1999, Cancer.
[6] J. Peterse,et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement , 1998, The Lancet.
[7] J. Pater,et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Bonadonna,et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Luini,et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] G. Hortobagyi,et al. Factors predicting long‐term survival for metastatic breast cancer patients treated with high‐dose chemotherapy and bone marrow support , 1994, Cancer.